Biliary Atresia Treatment Market, by Disease Type (Type I, Type II, and Type III), by Treatment Type (Medications (Bile Acids, Antibiotics, and Corticosteroids) and Surgery), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East,

Biliary Atresia Treatment Market, by Disease Type (Type I, Type II, and Type III), by Treatment Type (Medications (Bile Acids, Antibiotics, and Corticosteroids) and Surgery), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Biliary atresia is a disease that affects infants. In this disease, the bile ducts are inflamed and blocked right after the birth. Bile is a digestive fluid that is produced and released by the liver. It travels to the small intestine through the bile ducts, where it helps in digesting fats. As the bile ducts are blocked, bile remains in the liver, where it starts to destroy liver cells rapidly and cause cirrhosis, or scarring of the liver. Reason that causes the inflammation of the ducts is not known, but it may be due to infections, toxins, immune problems. The first sign or symptom of biliary atresia is jaundice. Other symptoms include dark brown urine, difficulty in gaining weight, pale colored stools, and enlarged spleen.
In maximum cases, biliary atresia manifests several weeks to months after birth, probably after inflammation and scarring of the extrahepatic (and occasionally intrahepatic) bile ducts. It is rarely present in premature infants or in neonates at birth (or is unrecognized in neonates). Biliary atresia needs treatment by liver specialists and surgeons. Babies with blocked bile ducts require a surgery, which is called the Kasai procedure. This allows bile to drain directly from the liver into the small intestine. At the start of the surgery, the doctor will perform a cholangiogram to check if bile ducts are blocked. If they’re not blocked, the baby won’t require the procedure. Prophylactic antibiotics are often prescribed for a year postoperatively in order to prevent ascending cholangitis. Drugs that increase bile production (choleretic agents), consisting of ursodiol about are frequently used postoperatively. Nutritional therapy including supplemental fat-soluble vitamins is essential to ensure adequate intake to support growth. Even with optimal therapy, about 50% of babies develop cirrhosis and require liver transplantation.
Market Dynamics
The need to develop a safe and effective drug and the ongoing clinical trials for biliary atresia are expected to drive the global biliary atresia treatment market growth over the forecast period. For instance, as of October 2021, pentoxifylline (PTX), a methylxanthine derivative, is under phase II of clinical trials. The trial's aim is to determine if PTX has sufficient biological activity against biliary atresia to warrant further study. PTX will be administered orally for 90 days as an adjunct to standard therapy, i.e., the Kasai procedure, if applicable.
Key features of the study:
This report provides in-depth analysis of the global biliary atresia treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global biliary atresia treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global biliary atresia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biliary atresia treatment market
Detailed Segmentation:
Global Biliary Atresia Treatment Market, By Disease Type:
Type I
Type II
Type III
Global Biliary Atresia Treatment Market, By Treatment Type:
Medications
Bile Acids
Antibiotics
Corticosteroids
Surgery
Global Biliary Atresia Treatment Market, By Region:
North America
Disease Type
Type I
Type II
Type III
Treatment Type
Medications
Bile acids
Antibiotics
Corticosteroids
Surgery
By Country
U.S.
Canada
Latin America
Disease Type
Type I
Type II
Type III
Treatment Type
Medications
Bile acids
Antibiotics
Corticosteroids
Surgery
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Disease Type
Type I
Type II
Type III
Treatment Type
Medications
Bile acids
Antibiotics
Corticosteroids
Surgery
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Disease Type
Type I
Type II
Type III
Treatment Type
Medications
Bile acids
Antibiotics
Corticosteroids
Surgery
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Disease Type
Type I
Type II
Type III
Treatment Type
Medications
Bile acids
Antibiotics
Corticosteroids
Surgery
By Country
GCC
Israel
Rest of Middle East
Africa
Disease Type
Type I
Type II
Type III
Treatment Type
Medications
Bile acids
Antibiotics
Corticosteroids
Surgery
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
AstraZeneca plc
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Eisai Co., Ltd.
Mirum Pharmaceuticals, Inc.
Pfizer Inc.
Albireo Pharma, Inc.
Novartis AG
Alkem Labs
Glenmark Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.